Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative

ABSTRACT

Disclosed is a compound containing a pyridine ring that can be synthesized in an industrially advantageous manner, and is useful as an intermediate for producing tetrazolyloxime derivatives that exhibit fungicidal activity (wherein R 0  represents a C 1-6  alkoxy group, C 1-6  alkoxy-C 1-6  alkoxy group or the like, R 1  represents a C 1-2  alkoxycarbonyl group, acetyl group or the like, Z represents a halogen atom, cyano group or the like, X represents a halogen atom, and n represents an integer of 0 to 3), and industrially advantageous production methods for producing 2-substituted amino-6-halomethylpyridine derivatives and tetrazolyloxime derivatives.

TECHNICAL FIELD

The present invention relates to (1) a compound containing a pyridinering that is ideal as an agrochemical intermediate, (2) a productionmethod that enables a 2-substituted amino-6-halomethylpyridinederivative, which is useful as a synthetic intermediate foragrochemicals and the like, to be obtained in high yield, and (3) anindustrially advantageous method for producing a tetrazolyloximederivative that exhibits a superior antagonistic effect against plantdiseases.

Priority is claimed on Japanese Patent Application No. 2010-056718,filed Mar. 12, 2010, Japanese Patent Application No. 2010-127207, filedJun. 2, 2010, and Japanese Patent Application No. 2010-115703, filed May19, 2010, the contents of which are incorporated herein by reference.

BACKGROUND ART

Examples of methods for producing halomethylpyridine derivatives includea method disclosed in Patent Document 1, in which2-chloro-5-chloromethylpyridine is produced by adding a chlorinatingagent such as oxalyl chloride dropwise to an acetonitrile solution of2-chloro-5-acetaminomethylpyridine and dimethylformamide, and thenheating the mixture at 80° C.

Patent Document 2 discloses a method for producing chloromethylpyridinesby reacting an aminomethylpyridine with a nitrosating agent or adiazotizing agent, in the presence of a diluent, and if necessary in thepresence of hydrogen chloride, and at a temperature within a range from−20° C. to +50° C.

Further, Patent Document 3 discloses a method for producing6-chloro-2-(chloromethyl)pyridine that features reducing6-chloro-2-(trichloromethyl)pyridine or6-chloro-2-(dichloromethyl)pyridine.

The tetrazolyloxime derivatives disclosed in Patent Document 4 and thelike exhibit excellent fungicidal activity, and are viewed as promisingcompounds for the active ingredients of plant disease control agents. Amethod that has been disclosed for producing such tetrazolyloximederivatives involves reacting a tetrazolylmethanone derivativerepresented by formula (A) with hydroxylamine to obtain atetrazolylhydroxyimino derivative represented by formula (B), andsubsequently reacting the tetrazolylhydroxyimino derivative with acompound represented by formula (C) in the presence of a base, therebyobtaining a tetrazolyloxime derivative represented by formula (D).

In relation to the present invention, Patent Documents 1 to 3 disclosemethods for producing halomethylpyridine derivatives. Further, PatentDocuments 4 and 5 disclose tetrazolyloxime derivatives having structuresthat are similar to that of the compound of the present invention, andthese tetrazolyloxime derivatives have been proposed for use asfungicides.

DOCUMENTS OF RELATED ART Patent Documents

-   [Patent Document 1]-   Japanese Unexamined Patent Application, First Publication No. Hei    08-259539-   [Patent Document 2]-   Japanese Unexamined Patent Application, First Publication No. Hei    07-017948-   [Patent Document 3]-   Japanese Unexamined Patent Application, First Publication No. Sho    56-43268-   [Patent Document 4]-   Japanese Unexamined Patent Application, First Publication No.    2003-137875-   [Patent Document 5]-   International Patent Publication No. WO 2003/016303

DISCLOSURE OF INVENTION Problems to be Solved by the Invention

The present invention has an object of providing (1) a compoundcontaining a pyridine ring that is ideal as an agrochemicalintermediate, (2) a production method that enables a 2-substitutedamino-6-halomethylpyridine derivative, which is useful as a syntheticintermediate for agrochemicals and the like, to be obtained in highyield, and (3) an industrially advantageous method for producing atetrazolyloxime derivative that exhibits a superior antagonistic effectagainst plant diseases.

Means to Solve the Problems

The inventors of the present invention conducted intensiveinvestigations aimed at achieving the above object. As a result, theydiscovered (1) that a compound containing a pyridine ring and having aspecific structure could be synthesized in an industrially advantageousmanner, and was useful as an intermediate in producing a tetrazolyloximederivative that exhibits fungicidal activity, (2) that by reacting a2-substituted amino-6-methylpyridine derivative and a brominating agentwithin an organic solvent, and then reacting the thus obtained reactionproduct with a phosphite ester and a base within an organic solvent, a2-substituted amino-6-bromomethylpyridine derivative could be producedin high yield, and (3) that by reacting a specific 2-substitutedamino-6-halomethylpyridine derivative and a tetrazolylhydroxyiminoderivative, a novel production intermediate composed of atetrazolyloxime derivative could be obtained, and that by reacting aspecific 2-substituted amino-6-halomethylpyridine derivative and atetrazolylhydroxyimino derivative, and then treating the thus obtainedreaction product with a base, a tetrazolyloxime derivative that exhibitsa superior antagonistic effect against plant diseases could be obtainedin an industrially advantageous manner. The present invention wascompleted as a result of conducting further investigations based onthese findings.

In other words, the present invention includes the aspects describedbelow.

[1] A compound containing a pyridine ring, represented by formula (1):

wherein R⁰ represents a C₁₋₆ alkoxy group, C₁₋₆ alkoxy-C₁₋₆ alkoxygroup, C₁₋₆ alkoxy-C₁₋₆ alkyl group, 1,3-dioxane-2-yl-C₁₋₆ alkyl group,or CR⁰¹C(═NOR⁰²) group (wherein each of R⁰¹ and R⁰² independentlyrepresents a C₁₋₆ alkyl group),

R¹ represents a C₁₋₂ alkoxycarbonyl group, an acetyl group, or a benzoylgroup that may be substituted with a nitro group,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other,

X represents a halogen atom, and

n represents the number of X substituents and is an integer of 0 to 3,and when n is 2 or more, the plurality of X atoms may be the same as, ordifferent from, each other.

[2] A method for producing a halogenated picoline derivative representedby formula (3), the method including a step B1 of reacting a compoundrepresented by formula (2) and a halogenating agent within an organicsolvent, and a step B2 of reducing the reaction product obtained in thestep 131,

wherein R^(1b) represents an unsubstituted or substituent-containingalkoxycarbonyl group,

R^(2b) represents an unsubstituted or substituent-containingalkoxycarbonyl group, unsubstituted or substituent-containing acylgroup, unsubstituted or substituent-containing aryloxycarbonyl group, orunsubstituted or substituent-containing heterocyclic oxycarbonyl group,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),and

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other,

wherein R^(1b), R^(2b), Z and m are the same as defined above, and Xrepresents a halogen atom.[3] The method for producing a halogenated picoline derivative accordingto [2] above, wherein the step B1 is performed in the presence of abase.[4] The method for producing a halogenated picoline derivative accordingto [2] or [3] above, wherein the organic solvent in the step B1 isbenzene or a halogenated hydrocarbon.[5] The method for producing a halogenated picoline derivative accordingto [2] or [3] above, wherein the step B2 is performed in the presence ofa phase transfer catalyst.

-   [6] The method for producing a halogenated picoline derivative    according to [2] or [3] above, wherein the halogenating agent is a    brominating agent, and X represents a bromine atom.-   [7] A method for producing a brominated picoline derivative    represented by formula (6), the method including reacting a    brominated picoline derivative represented by formula (4) and/or    formula (5), a phosphite ester, and a base within an organic    solvent,

wherein R^(1b) represents an unsubstituted or substituent-containingalkoxycarbonyl group,

R^(2b) represents an unsubstituted or substituent-containingalkoxycarbonyl group, unsubstituted or substituent-containing acylgroup, unsubstituted or substituent-containing aryloxycarbonyl group, orunsubstituted or substituent-containing heterocyclic oxycarbonyl group,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),and

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other.

[8] A method for producing a tetrazolyloxime derivative represented byformula (10), the method including a step C1 of reacting a halogenatedpicoline derivative represented by formula (7) with atetrazolylhydroxyimino derivative represented by formula (8) to obtain atetrazolyloxime derivative represented by formula (9), and a step C2 oftreating the tetrazolyloxime derivative represented by formula (9)obtained in the step C1 with a base,

wherein within formula (7), R^(1C) represents an unsubstituted orsubstituent-containing alkyl group, or an unsubstituted orsubstituent-containing alkoxy group,

R^(2C) represents an unsubstituted or substituent-containingalkoxycarbonyl group, or an unsubstituted or substituent-containing acylgroup,

X represents a halogen atom,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),and

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other, and

within formula (8), Y represents an unsubstituted orsubstituent-containing alkyl group,

A represents a halogen atom, unsubstituted or substituent-containingalkyl group, unsubstituted or substituent-containing alkoxy group, cyanogroup, unsubstituted or substituent-containing alkylsulfonyl group,nitro group, or unsubstituted or substituent-containing aryl group, and

n_(c) represents the number of A substituents and is an integer of 0 to5, and when n_(c) is 2 or more, the plurality of the A substituents maybe the same as, or different from, each other.

[9] A tetrazolyloxime derivative represented by formula (9):

wherein R^(1C) represents an unsubstituted or substituent-containingalkyl group, or an unsubstituted or substituent-containing alkoxy group,

R^(2C) represents an unsubstituted or substituent-containingalkoxycarbonyl group, or an unsubstituted or substituent-containing acylgroup,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other,

Y represents an unsubstituted or substituent-containing alkyl group,

A represents a halogen atom, unsubstituted or substituent-containingalkyl group, unsubstituted or substituent-containing alkoxy group, cyanogroup, unsubstituted or substituent-containing alkylsulfonyl group,nitro group, or unsubstituted or substituent-containing aryl group, and

n_(c) represents the number of A substituents and is an integer of 0 to5, and when n_(c) is 2 or more, the plurality of the A substituents maybe the same as, or different from, each other.

[10] A method for producing a tetrazolyloxime derivative represented byformula (9), the method including a step C1 of reacting a halogenatedpicoline derivative represented by formula (7) with atetrazolylhydroxyimino derivative represented by formula (8),

wherein R^(1C) represents an unsubstituted or substituent-containingalkyl group, or an unsubstituted or substituent-containing alkoxy group,

R^(2C) represents an unsubstituted or substituent-containingalkoxycarbonyl group, or an unsubstituted or substituent-containing acylgroup,

X represents a halogen atom,

Z represents a halogen atom, cyano group, nitro group, hydroxyl group,thiol group, formyl group, carboxyl group, unsubstituted orsubstituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, unsubstituted or substituent-containing alkyl group,unsubstituted or substituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group, and p represents the numberof oxygen atoms shown in the parentheses, and is an integer of 0 to 2),

m represents the number of Z substituents and is an integer of 0 to 3,and when m is 2 or more, the plurality of Z substituents may be the sameas, or different from, each other,

Y represents an unsubstituted or substituent-containing alkyl group,

A represents a halogen atom, unsubstituted or substituent-containingalkyl group, unsubstituted or substituent-containing alkoxy group, cyanogroup, unsubstituted or substituent-containing alkylsulfonyl group,nitro group, or unsubstituted or substituent-containing aryl group, and

n_(c) represents the number of A substituents and is an integer of 0 to5, and when n_(c) is 2 or more, the plurality of the A substituents maybe the same as, or different from, each other.

Effects of the Invention

The compound containing a pyridine ring according to the presentinvention can be synthesized in an industrially advantageous manner, andis useful as an intermediate for producing tetrazolyloxime derivativesthat exhibit fungicidal activity. Further, the production method of thepresent invention enables 2-substituted amino-6-halomethylpyridinederivatives to be obtained with high selectivity and in high yield, andenables the production, in an industrially advantageous manner, oftetrazolyloxime derivatives that exhibit excellent antagonistic effectsagainst plant diseases.

EMBODIMENTS OF THE INVENTION

1. Compound Containing a Pyridine Ring that is Ideal as an AgrochemicalIntermediate

A compound containing a pyridine ring according to the present inventionis a compound represented by formula (1).

The compound may be synthesized in the manner described below.

In the case where n=0,

wherein R⁰, Z and m are the same as defined above, and L represents aleaving group such as a halogen atom.

The compound represented by formula (12) according to the presentinvention (hereafter referred to as “compound (12)”) may be obtained bytreating the compound represented by formula (11) (hereafter referred toas “compound (11)”) with a compound represented by R¹-L. L represents aleaving group such as a halogen atom.

Examples of the compound represented by R¹-L include methoxycarbonylchloride, ethoxycarbonyl chloride, acetyl chloride, benzoyl chloride andp-nitrobenzoyl chloride.

In the case where n=1 to 3,

wherein R⁰, R¹, Z, m and X are the same as defined above, and n′represents an integer of 1 to 3.

The compound represented by formula (13) according to the presentinvention (hereafter referred to as “compound (13)”) may be obtained byhalogenating the compound (12). The halogenation reaction may beconducted using a conventional method.

In the halogenation reaction, a simple halogen, sulfuryl chloride,phosphorus pentachloride, N-chlorosuccinimide, N-bromosuccinimide,1,3-dibromo-5,5-dimethylhydantoin, anhydrous copper chloride, aluminumchloride, or the like may be used.

R⁰ in the compound (I) according to the present invention represents aC₁₋₆ alkoxy group, C₁₋₆ alkoxy-C₁₋₆ alkoxy group, C₁₋₆ alkoxy-C₁₋₆ alkylgroup, 1,3-dioxane-2-yl-C₁₋₆ alkyl group, or CR⁰¹C(═NOR⁰²) group(wherein each of R⁰¹ and R⁰² independently represents a C₁₋₆ alkylgroup).

Examples of the C₁₋₆ alkoxy group for R⁰ include a methoxy group, ethoxygroup, n-propoxy group, i-propoxy group, n-butoxy group, i-butoxy group,s-butoxy group, t-butoxy group, n-pentyloxy group and n-hexyloxy group.

Examples of the C₁₋₆ alkoxy-C₁₋₆ alkoxy group for R⁰ include amethoxymethoxy group, ethoxymethoxy group, methoxyethoxy group,3-ethoxypropoxy group, 2-ethoxybutoxy group, 4-butoxybutoxy group,1-butoxypentoxy group, 3-isopropoxy-2-methylpropoxy group and1-methoxy-2-ethoxyethoxy group.

Examples of the C₁₋₆ alkoxy-C₁₋₆ alkyl group for R⁰ include amethoxymethyl group, ethoxymethyl group, methoxyethyl group,methoxypropyl group, ethoxybutyl group, methoxybutyl group, methoxyhexylgroup, propoxyoctyl group, 2-methoxy-1,1-dimethylethyl group,1-ethoxy-1-methylethyl group and 1-ethoxy-2-methoxyethyl group.

Examples of the 1,3-dioxane-2-yl-C₁₋₆ alkyl group for R⁰ include a1,3-dioxane-2-yl-methyl group and 1,3-dioxane-2-yl-ethyl group.

Each of R⁰¹ and R⁰² in the CR⁰¹C(═NOR⁰²) group for R⁰ independentlyrepresents a C₁₋₆ alkyl group such as a methyl group, ethyl group,n-propyl group, i-propyl group, n-butyl group or n-hexyl group.

Specific examples of the CR⁰¹C(═NOR⁰²) group for R⁰ includeCH₃C(═NOCH₃), CH₃C(═NOC₃H) and C₂H₅C(═NOCH₃).

R¹ in the compound (I), the compound (12) and the compound (13)according to the present invention represents a C₁₋₂ alkoxycarbonylgroup, an acetyl group, or a benzoyl group that may be substituted witha nitro group.

Examples of the C₁₋₂ alkoxycarbonyl group for R¹ include amethoxycarbonyl group and an ethoxycarbonyl group.

Examples of the benzoyl group that may be substituted with a nitro groupfor R¹ include a p-nitrobenzoyl group.

Further, Z and m in formula (1), formula (12) and formula (13) are thesame as Z and m described below for formula (7).

X in formula (1) represents a halogen atom, and examples of the halogenatom include a fluorine atom, chlorine atom, bromine atom and iodineatom. Of these, a chlorine atom or a bromine atom is preferred, and abromine atom is particularly desirable.

The compound (1) according to the present invention is useful as anintermediate for producing a tetrazolyloxime derivative that exhibitsfungicidal activity.

2. Production method that enables a 2-substitutedamino-6-halomethylpyridine derivative, Which is Useful as a SyntheticIntermediate for Agrochemicals and the Like, to be Obtained In HighYield

A method for producing a halogenated picoline derivative according tothe present invention includes a step B1 of reacting a compoundrepresented by formula (2) and a halogenating agent within an organicsolvent, and a step B2 of reducing the reaction product obtained in thestep B1.

[Step B1]

The raw material used in the production method of the present inventionis a compound represented by formula (2).

R^(1b) in formula (2) represents an unsubstituted orsubstituent-containing alkoxycarbonyl group. There are no particularlimitations on the substituent, provided it is inactive in thehalogenation reaction. The alkoxy group within the alkoxycarbonyl grouppreferably contains 1 to 6 carbon atoms.

Specific examples of the unsubstituted alkoxycarbonyl group for R^(1b)include a methoxycarbonyl group, ethoxycarbonyl group, i-propoxycarbonylgroup, n-propoxycarbonyl group, n-butoxycarbonyl group, i-butoxycarbonylgroup, s-butoxycarbonyl group and t-butoxycarbonyl group.

Examples of the substituent-containing alkoxycarbonyl group for R^(1b)include a cyanomethoxycarbonyl group, 1-cyanoethoxycarbonyl group,2-cyanoethoxycarbonyl group, nitromethoxycarbonyl group,chloromethoxycarbonyl group, fluoromethoxycarbonyl group,difluoromethoxycarbonyl group, trifluoromethoxycarbonyl group,2-fluoroethoxycarbonyl group, 2,2,2-trifluoroethoxycarbonyl group,methoxymethoxycarbonyl group, ethoxymethoxycarbonyl group,1-methoxyethoxycarbonyl group, 2-methoxyethoxycarbonyl group and2-chloroethoxymethoxycarbonyl group.

Among these, R^(1b) is preferably an unsubstituted alkoxycarbonyl group,more preferably an unsubstituted alkoxycarbonyl group in which thealkoxy group contains 1 to 6 carbon atoms, and most preferably at-butoxycarbonyl group.

R^(2b) in formula (2) represents an unsubstituted orsubstituent-containing alkoxycarbonyl group, unsubstituted orsubstituent-containing acyl group, unsubstituted orsubstituent-containing aryloxycarbonyl group, or unsubstituted orsubstituent-containing heterocyclic oxycarbonyl group.

Examples of the unsubstituted alkoxycarbonyl group for R^(2b) include amethoxycarbonyl group, ethoxycarbonyl group, i-propoxycarbonyl group,n-propoxycarbonyl group, n-butoxycarbonyl group, i-butoxycarbonyl group,s-butoxycarbonyl group and t-butoxycarbonyl group.

Examples of the substituent-containing alkoxycarbonyl group for R^(2b)include a cyanomethoxycarbonyl group, 1-cyanoethoxycarbonyl group,2-cyanoethoxycarbonyl group, nitromethoxycarbonyl group,chloromethoxycarbonyl group, fluoromethoxycarbonyl group,difluoromethoxycarbonyl group, trifluoromethoxycarbonyl group,2-fluoroethoxycarbonyl group, 2,2,2-trifluoroethoxycarbonyl group,methoxymethoxycarbonyl group, ethoxymethoxycarbonyl group,1-methoxyethoxycarbonyl group, 2-methoxyethoxycarbonyl group and2-chloroethoxymethoxycarbonyl group.

The acyl group for R^(2b) is a group in which a hydrogen atom, or analkyl group, alkenyl group, alkynyl group, aryl group or heterocyclicgroup, is bonded to a carbonyl group.

Examples of the unsubstituted acyl group include a formyl group;alkylcarbonyl groups such as an acetyl group, propionyl group,n-propylcarbonyl group, n-butylcarbonyl group, octanoyl group,i-propylcarbonyl group, i-butylcarbonyl group, pivaloyl group andisovaleryl group; alkenylcarbonyl groups such as an acryloyl group andmethacryloyl group; alkynylcarbonyl groups such as a propioloyl group;arylcarbonyl groups such as a benzoyl group; and heterocyclic carbonylgroups such as a 2-pyridylcarbonyl group and thienylcarbonyl group.

Examples of the substituent-containing acyl group for R^(2b) include afluoroacetyl group, chloroacetyl group, nitroacetyl group, cyanoacetylgroup, methoxyacetyl group, dibromoacetyl group, trifluoroacetyl group,trichloroacetyl group, tribromoacetyl group, 3,3,3-trifluoropropionylgroup, 3,3,3-trichloropropionyl group, 2,2,3,3,3-pentafluoropropionylgroup and 4-chlorobenzoyl group.

Examples of the unsubstituted aryloxycarbonyl group for R^(2b) include aphenyloxycarbonyl group, 1-naphthyloxycarbonyl group,2-naphthyloxycarbonyl group, azulenyloxycarbonyl group,indenyloxycarbonyl group, indanyloxycarbonyl group andtetralinyloxycarbonyl group.

Examples of the substituent-containing aryloxycarbonyl group for R^(2b)include a 6-methylphenyloxycarbonyl group, 4-methylphenyloxycarbonylgroup, 4-fluorophenyloxycarbonyl group, 4-chlorophenyloxycarbonyl group,2,4-dichlorophenyloxycarbonyl group, 3,4-dichlorophenyloxycarbonylgroup, 3,5-dichlorophenyloxycarbonyl group,2,6-difluorophenyloxycarbonyl group, 4-trifluoromethylphenyl oxycarbonylgroup, 4-methoxyphenyloxycarbonyl group, 3,4-dimethoxyphenyloxycarbonylgroup, 3,4-methylenedioxyphenyloxycarbonyl group,3-phenoxyphenyloxycarbonyl group, 4-trifluoromethoxyphenyloxycarbonylgroup and 4-methoxy-1-naphthyloxycarbonyl group.

Examples of the unsubstituted heterocyclic oxycarbonyl group for R^(2b)include unsaturated heterocyclic 5-membererd ring oxycarbonyl groupssuch as a furan-2-yloxycarbonyl group, furan-3-yloxycarbonyl group,thiophen-2-yloxycarbonyl group, thiophen-3-yloxycarbonyl group,pyrrol-2-yloxycarbonyl group, pyrrol-3-yloxycarbonyl group,oxazol-2-yloxycarbonyl group, oxazol-4-yloxycarbonyl group,oxazol-5-yloxycarbonyl group, thiazol-2-yloxycarbonyl group,thiazol-4-yloxycarbonyl group, thiazol-5-yloxycarbonyl group,isooxazol-3-yloxycarbonyl group, isooxazol-4-yloxycarbonyl group,isooxazol-5-yloxycarbonyl group, isothiazol-3-yloxycarbonyl group,isothiazol-4-yloxycarbonyl group, isothiazol-5-yloxycarbonyl group,imidazol-2-yloxycarbonyl group, imidazol-4-yloxycarbonyl group,imidazol-5-yloxycarbonyl group, pyrazol-3-yloxycarbonyl group,pyrazol-4-yloxycarbonyl group, pyrazol-5-yloxycarbonyl group,1,3,4-oxadiazol-2-yloxycarbonyl group, 1,3,4-thiadiazol-2-yloxycarbonylgroup, 1,2,3-triazol-4-yloxycarbonyl group,1,2,4-triazol-3-yloxycarbonyl group and 1,2,4-triazol-5-yloxycarbonylgroup; unsaturated heterocyclic 6-membererd ring oxycarbonyl groups suchas a pyridin-2-yloxycarbonyl group, pyridin-3-yloxycarbonyl group,pyridin-4-yloxycarbonyl group, 5-chloro-3-pyridyloxycarbonyl group,3-trifluoromethyl-2-pyridyloxycarbonyl group, pyridazin-3-yloxycarbonylgroup, pyridazin-4-yloxycarbonyl group, pyrazin-2-yloxycarbonyl group,pyrimidin-5-yloxycarbonyl group, 1,3,5-triazin-2-yloxycarbonyl group and1,2,4-triazin-3-yloxycarbonyl group; and saturated or partiallyunsaturated heterocyclic oxycarbonyl groups such as atetrahydrofuran-2-yloxycarbonyl group, tetrahydropyran-4-yloxycarbonylgroup, piperidin-3-yloxycarbonyl group, pyrrolidin-2-yloxycarbonylgroup, morpholino-oxycarbonyl group, piperidino-oxycarbonyl group,piperazino-oxycarbonyl group, N-methylpiperazino-oxycarbonyl group,aziridino-oxycarbonyl group, azetidino-oxycarbonyl group,pyrrolidino-oxycarbonyl group and oxazolin-2-yloxycarbonyl group.

Examples of the substituent-containing heterocyclic oxycarbonyl groupfor R^(2b) include a 3-trifluoromethylpyridin-2-yloxycarbonyl group,4-trifluoromethoxy-2-pyridyloxycarbonyl group,3-methyl-1-pyrazolyloxycarbonyl group,4-trifluoromethyl-1-imidazolyloxycarbonyl group and3,4-difluoropyrrolidino-oxycarbonyl group.

Among these groups, R^(2b) in formula (2) is preferably an unsubstitutedor substituent-containing benzoyl group. There are no particularlimitations on the substituent on the benzoyl group, provided it isinactive in the halogenation reaction.

Specific examples of the substituent-containing benzoyl group for R^(2b)include a 2,6-dimethoxybenzoyl group, 3,5-nitrobenzoyl group,2,4,6-trichlorobenzoyl group and 4-chlorobenzoyl group.

Z and m in formula (2) are the same as Z and m described below forformula (7).

There are no particular limitations on the halogenating agent used inthe step B1, and any of the compounds used for performing halogenationin conventional synthesis reactions may be used.

Examples of the halogenating agent include compounds which themselvesfunction as halogenating agents, and compounds which are converted to ahalogenating agent within the reaction system. Specific examples of thehalogenating agent include bromine (Br₂), chlorine (Cl₂), hydrogenbromide, hydrogen chloride; metal bromides such as lithium bromide,potassium bromide, sodium bromide, magnesium bromide, calcium bromide,barium bromide, aluminum bromide, phosphorus tribromide and phosphoruspentabromide; ammonium bromides such as ammonium bromide,tetramethylammonium bromide, tetraethylammonium bromide andtetra-n-butylammonium bromide; as well as trimethylsilyl bromide, BrF,BrF₃, BrF₅, BrCl, BrCl₃, bromine-pyridine complex,1,3-dibromo-5,5-dimethylhydantoin, 1,3-diiodo-5,5-dimethylhydantoin,thionyl bromide, hypochlorites, hypobromites, cyanuric chloride,N-bromosuccinimide (NBS), N-chlorosuccinimide (NCS), N-iodosuccinimide(NIS), dimethyldichlorohydantoin and trichloroisocyanuric acid. Amongthese, brominating agents are preferred, and dimethyldibromohydantoin isparticularly preferred.

Although there are no particular limitations on the amount used of thehalogenating agent, the amount of halogen atoms per 1 mol of thecompound represented by formula (2) is preferably within a range from0.1 to 10 mols, and more preferably from 1 to 5 mols.

Examples of the organic solvent used in the step B1 include ethers suchas diethyl ether, butyl methyl ether, tetrahydrofuran, dioxane anddimethoxyethane; halogenated hydrocarbons such as chlorobenzene,dichlorobenzene, dichloromethane, chloroform, carbon tetrachloride,dichloroethane, trichloroethane and dichloroethylene; aromatichydrocarbons such as benzene, toluene and xylene; aliphatic hydrocarbonssuch as pentane, hexane, heptane, octane and cyclohexane; esters such asmethyl acetate, ethyl acetate and propyl acetate; polar aprotic solventssuch as acetone, methyl ethyl ketone, cyclohexanone, acetonitrile,propionitrile, N,N-dimethylformamide, dimethylsulfoxide,hexamethylphosphoric triamide, sulfolane, dimethylacetamide andN-methylpyrrolidone; protic solvents such as acetic acid; and water.

Of these, from the viewpoints of suppressing side reactions, andensuring selective halogenation of the methyl group in the compoundrepresented by formula (2), benzene or a halogenated hydrocarbon ispreferable.

In the present invention, the step B1 is preferably performed in thepresence of a base. When a base is present in the reaction system, sidereactions are suppressed, and the halogenation of the methyl group inthe compound represented by formula (2) proceeds with betterselectivity.

Examples of the base include alkali metal hydroxides such as sodiumhydroxide and potassium hydroxide; alkaline earth metal hydroxides suchas magnesium hydroxide and calcium hydroxide; carbonates such as sodiumcarbonate, potassium carbonate, magnesium carbonate, calcium carbonate,sodium hydrogen carbonate and potassium hydrogen carbonate; hydridessuch as sodium hydride and calcium hydride; metal alkoxides such assodium methoxide, sodium ethoxide and magnesium methoxide; and organicbases such as triethylamine, diisopropylethylamine, pyridine,N,N-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,4-(dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene and1,5-diazabicyclo[4.3.0]non-5-ene. Any one of these bases may be usedalone, or a combination of two or more bases may be used. Among theabove bases, sodium hydrogen carbonate is preferred.

The amount used of the base is preferably within a range from 0.1 to 10mols, and more preferably from 0.5 to 2 mols, per 1 mol of the compoundrepresented by formula (2).

There are no particular limitations on the procedure and the likeadopted for the reaction between the compound represented by formula (2)and the halogenating agent. For example, the compound represented byformula (2), and where necessary sodium hydrogen carbonate, may be addedto the organic solvent, and the halogenating agent then added graduallyto the reaction mixture to cause the reaction to proceed. Thetemperature during the period from the start of the reaction to thecompletion of the reaction may be either kept at a constant temperatureor varied, but is preferably within a range from 0 to 200° C., and morepreferably from room temperature to 150° C.

By conducting the step B1, the methyl group within the compoundrepresented by formula (2) is selectively halogenated. As a result, areaction product containing a monohalogenated picoline derivativerepresented by formula (3), a dihalogenated picoline derivativerepresented by formula (14) and/or a trihalogenated picoline derivativerepresented by formula (15) is obtained. Subjecting the reaction productto purification by conventional methods to isolate the monohalogenatedpicoline derivative represented by formula (3) in a high degree ofpurity requires considerable cost and time. Accordingly, in the presentinvention, the step B2 described below is performed.

[Step B2]

There are no particular limitations on the method used for reducing themixed reaction product containing the compounds represented by formula(3), formula (14) and formula (15) obtained in the step B1.

Examples of methods that may be used include a method in which thereaction product obtained in the step B1 is reacted in the presence ofan acid and a metal within an organic solvent, and a method in whichhydrogen is added to and reacted with the reaction product obtained inthe step B1 within an organic solvent.

Examples of the acid used in the above method include inorganic acidssuch as hydrochloric acid, sulfuric acid and phosphoric acid, andorganic acids such as acetic acid, propionic acid and butyric acid.

Examples of the metal used in the above method include zinc, iron, tin,cobalt, nickel and aluminum. The metal is preferably in the form of afine powder.

There are no particular limitations on the amounts used of the acid andthe metal, provided they are sufficient to generate the amount ofhydrogen required to effect the reduction reaction. The required amountof hydrogen is preferably within a range from 0.6 to 1.5 mols per 1 molof the halogenated picoline derivative represented by formula (14), andis preferably within a range from 1.2 to 3.0 mols per 1 mol of thehalogenated picoline derivative represented by formula (15).

The reduction reaction is typically conducted at a temperature within arange from −20° C. to reflux temperature, and preferably at atemperature from 20 to 40° C.

In those cases where the reduction is performed on a reaction product inwhich X represents a bromine atom, which is obtained by using abrominating agent as the halogenating agent in the step B1, a methodthat includes reacting the reaction product obtained in the step B1,namely the brominated picoline derivative represented by formula (4)and/or the brominated picoline derivative represented by formula (5),with a phosphite ester and a base within an organic solvent isparticularly desirable.

The phosphite ester used in the above method is represented by P(OR)₃,wherein the oxidation number of phosphorus is +3. R represents ahydrogen atom, an alkyl group, an aryl group or the like, and at leastone of the three R groups is a group other than a hydrogen atom.

Examples of the phosphite ester include triphenyl phosphite,tris(nonylphenyl) phosphite, tris(2,4-di-tert-butylphenyl)phosphite,trinonyl phosphite, tridecyl phosphite, trioctyl phosphite, trioctadecylphosphite, distearylpentaerythritol diphosphite, tricyclohexylphosphite, monobutyldiphenyl phosphite, monooctyldiphenyl phosphite,distearylpentaerythritol diphosphite,bis(2,4-di-tert-butylphenyl)pentaerythritol phosphite,bis(2,6-di-tert-butyl-4-methylphenyl)pentaerythritol phosphite,2,2-methylene-bis(4,6-di-tert-butylphenyl)octyl phosphite, dimethylphosphite, diethyl phosphite, trimethyl phosphite and triethylphosphite.

The amount used of the phosphite ester is preferably within a range from0.1 to 20 mols per 1 mol of the brominated picoline derivativerepresented by formula (4), and is preferably within a range from 0.2 to40 mols per 1 mol of the brominated picoline derivative represented byformula (5).

Examples of the base used in the above method include alkali metalhydroxides such as sodium hydroxide and potassium hydroxide; alkalineearth metal hydroxides such as magnesium hydroxide and calciumhydroxide; carbonates such as sodium carbonate, potassium carbonate,magnesium carbonate and calcium carbonate; hydrides such as sodiumhydride and calcium hydride; metal alkoxides such as sodium methoxide,sodium ethoxide and magnesium methoxide; and organic bases such astriethylamine, diisopropylethylamine, pyridine,N,N-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,4-(dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene and1,5-diazabicyclo[4.3.0]non-5-ene.

The amount used of the base is preferably within a range from 0.1 to 10mols per 1 mol of the brominated picoline derivative represented byformula (4), and is preferably within a range from 0.2 to 20 mols per 1mol of the brominated picoline derivative represented by formula (5).

There are no particular limitations on the procedure and the likeadopted for the reaction between the reaction product obtained in thestep B1, the phosphite ester and the base. For example, the reaction maybe conducted by gradually adding the phosphite ester, the base, andwhere necessary a phase transfer catalyst, to an organic solventsolution containing the reaction product obtained in the step B1. Thetemperature during the period from the start of the reaction to thecompletion of the reaction may be either kept at a constant temperatureor varied, but is preferably within a range from −70° C. to +100° C.,and more preferably from −10° C. to +50° C.

There are no particular limitations on the organic solvent used in thestep B2, and examples thereof include the same organic solventsavailable in the step B1. The reaction product need not necessarily berecovered from the reaction solution obtained in the step B1, and thereaction solution may simply be used, as is, within the step B2.

In the present invention, the step B2 is preferably performed in thepresence of a phase transfer catalyst.

Examples of the phase transfer catalyst include quaternary ammoniumsalts; quaternary phosphonium salts such as tetrabutylphosphoniumchloride, tetrabutylphosphonium bromide, benzyltrimethylphosphoniumchloride and benzyltrimethylphosphonium bromide; and macrocyclicpolyethers such as 12-crown-4, 18-crown-6 and benzo-18-crown-6. Amongthese, the quaternary ammonium salts are preferred.

Examples of the quaternary ammonium salts include chlorides such astetramethylammonium chloride, tetraethylammonium chloride,tetra-n-propylammonium chloride, benzyltrimethylammonium chloride,benzyltriethylammonium chloride and benzyltripropylammonium chloride;bromides such as tetramethylammonium bromide, tetraethylammoniumbromide, tetra-n-propylammonium bromide, tetrabutylammonium bromide,benzyltrimethylammonium bromide, benzyltriethylammonium bromide andbenzyltripropylammonium bromide; and iodides such as tetramethylammoniumiodide, tetraethylammonium iodide, tetra-n-propylammonium iodide,benzyltrimethylammonium iodide, benzyltriethylammonium iodide andbenzyltripropylammonium iodide. Among these, tetrabutylammonium bromideis preferred.

The amount used of the phase transfer catalyst is preferably within arange from 0.001 to 10 mols, and more preferably from 0.01 to 1 mol, per1 mol of the compound represented by formula (2). By using the phasetransfer catalyst in an amount that satisfies the range, the targetproduct can be obtained in good yield.

By conducting the step B2, the dihalogenated picoline derivativerepresented by formula (14) and/or the trihalogenated picolinederivative represented by formula (15) are converted to themonohalogenated picoline derivative represented by formula (3). As aresult, the content ratio of the monohalogenated picoline derivativerepresented by formula (3) within the reaction system is increased, andisolation thereof becomes easy.

Following completion of each of the reactions in the above steps B1 andB2, typical post-processing operations may be performed. The targetedmonohalogenated picoline derivative represented by formula (3) can thenbe isolated. Further, if further purification of the product isnecessary, then conventional purification methods such as distillation,extraction, recrystallization or column chromatography may be employed.

The structure of the target product may be identified and confirmed bymeasuring the ¹H-NMR spectrum, IR spectrum and mass spectrum, and byelemental analysis and the like.

The halogenated picoline derivative obtained using the production methodof the present invention is useful as a production intermediate for theactive ingredients of agrochemical formulations that assist the growthof agricultural and horticultural crops, as a production intermediatefor the active ingredients of antifouling agents that prevent theadhesion of crustaceans and shellfish, as a production intermediate forthe active ingredients of fungicides, and as a production intermediatefor the active ingredients of antibacterial and moldproofing reagentsfor walls and bathrooms, or shoes and clothing. By employing theproduction intermediate, the active ingredients of agrochemicalformulations, fungicides, and antibacterial and moldproofing reagentscan be produced inexpensively and efficiently.

3. Industrially Advantageous Method for Producing a TetrazolyloximeDerivative that Exhibits a Superior Antagonistic Effect Against PlantDiseases

A tetrazolyloxime derivative represented by formula (9) according to thepresent invention is a novel compound and is useful as a productionintermediate for a tetrazolyloxime derivative represented by formula(10).

A method for producing the tetrazolyloxime derivative represented byformula (9) includes a step C1 of reacting the halogenated picolinederivative represented by formula (7) with a tetrazolylhydroxyiminoderivative represented by formula (8).

Further, a method for producing the tetrazolyloxime derivativerepresented by formula (10) includes the above step C1, and a step C2 oftreating the reaction product obtained in the step C1 with a base.

[Step C1]

The raw material used in the production method according to the presentinvention is the halogenated picoline derivative represented by formula(7).

R^(1C) in formula (7) represents an unsubstituted orsubstituent-containing alkyl group, or an unsubstituted orsubstituent-containing alkoxy group. There are no particular limitationson the substituent in R^(1C), provided it is inactive in the reactionwith the tetrazolylhydroxyimino derivative represented by formula (8).

The alkyl group for R^(1C) may be a linear, branched or cyclic group.Further, the alkyl group preferably contains 1 to 6 carbon atoms.

Examples of the unsubstituted alkyl group include a methyl group, ethylgroup, n-propyl group, i-propyl group, n-butyl group, i-butyl group,s-butyl group, t-butyl group, n-pentyl group, n-octyl group, cyclopropylgroup, cyclobutyl group, cyclopentyl group, cyclohexyl group,cycloheptyl group, 2,2-dimethylcyclopropyl group and menthyl group.

Examples of the substituent-containing alkyl group include achloromethyl group, fluoromethyl group, trifluoromethyl group,methoxymethyl group, ethoxymethyl group, methoxyethyl group,methoxypropyl group, ethoxybutyl group, methoxybutyl group, methoxyhexylgroup, propoxyoctyl group, 2-methoxy-1,1-dimethylethyl group,1-ethoxy-1-methylethyl group, carbomethoxymethyl group,1-carboethoxy-2,2-dimethyl-3-cyclopropyl group, hydroxymethyl group,hydroxyethyl group and 1-hydroxypropyl group. The substituent-containingalkyl group is preferably a haloalkyl group.

The alkoxy group for R^(1C) may be a linear, branched or cyclic group.Further, the alkoxy group preferably contains 1 to 6 carbon atoms.

Examples of the unsubstituted alkoxy group include a methoxy group,ethoxy group, n-propoxy group, i-propoxy group, n-butoxy group, i-butoxygroup, s-butoxy group, t-butoxy group, n-pentyloxy group, n-hexyloxygroup, n-decyloxy group, cyclopropyloxy group, cyclobutyloxy group,cyclopentyloxy group, cyclohexyloxy group and menthyloxy group.

Examples of the substituent-containing alkoxy group include achloromethoxy group, fluoromethoxy group, trifluoromethoxy group,methoxymethoxy group, ethoxymethoxy group, methoxyethoxy group,3-ethoxypropoxy group, 2-ethoxybutoxy group, 4-butoxybutoxy group,1-butoxypentoxy group, fluoromethoxymethoxy group,dichloromethoxymethoxy group, 1,2-dibromo-3-methoxypropoxy group and3-isopropoxy-2-methylpropoxy group.

R^(2C) in formula (7) represents an unsubstituted orsubstituent-containing alkoxycarbonyl group, or an unsubstituted orsubstituent-containing acyl group, and specific examples thereof includethe same groups as those described above for R^(2b).

Among the groups, R^(2C) in formula (7) is preferably an unsubstitutedor substituent-containing benzoyl group.

Examples of the substituent-containing benzoyl group include a2,6-dimethoxybenzoyl group, 3,5-nitrobenzoyl group,2,4,6-trichlorobenzoyl group and 4-chlorobenzoyl group.

X in formula (7) represents a halogen atom. Examples of the halogen atominclude a fluorine atom, chlorine atom, bromine atom and iodine atom. Ofthese, a chlorine atom or a bromine atom is preferred.

Z in formula (7) represents a halogen atom, cyano group, nitro group,hydroxyl group, thiol group, formyl group, carboxyl group, unsubstitutedor substituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³.

Examples of the halogen atom for Z include the same atoms as thosedescribed above for the halogen atom for X.

The unsubstituted amino group for Z is a group having a structurerepresented by —NH₂. Examples of the substituent-containing amino groupinclude a methylamino group, dimethylamino group, methylethylaminogroup, diethylamino group, t-butoxycarbonylmethylamino group,t-butoxycarbonylamino group, acetylmethylamino group, acetylethylaminogroup and benzoylmethylamino group.

Examples of the unsubstituted or substituent-containing alkyl group forZ include the same groups as those described above for the unsubstitutedor substituent-containing alkyl group for R^(1C).

The unsubstituted or substituent-containing alkenyl group for Zpreferably contains 2 to 8 carbon atoms.

Examples of the unsubstituted alkenyl group include a vinyl group,1-propenyl group, 2-propenyl group, 1-butenyl group, 2-butenyl group,3-butenyl group, 1-methyl-2-propenyl group, 2-methyl-2-propenyl group,1-pentenyl group, 2-pentenyl group, 3-pentenyl group, 4-pentenyl group,1-methyl-2-butenyl group, 2-methyl-2-butenyl group, 1-hexenyl group,2-hexenyl group, 3-hexenyl group, 4-hexenyl group and 5-hexenyl group.

Examples of the substituent-containing alkenyl group include a2-chloroethenyl group, 2-fluoroethenyl group, 3,3,3-trifluoro-1-pentenylgroup, 1,2,2-trifluoroethenyl group, 2,3,3-trifluoro-2-propenyl group,2,3,3-triiodo-2-propenyl group and 2-methoxyethenyl group.

The unsubstituted or substituent-containing alkynyl group for Zpreferably contains 2 to 8 carbon atoms.

Examples of the unsubstituted alkynyl group include an ethynyl group,1-propynyl group, 2-propynyl group, 1-butynyl group, 2-butynyl group,3-butynyl group, 1-methyl-2-propynl group, 2-methyl-3-butynyl group,1-pentynyl group, 2-pentynyl group, 3-pentynyl group, 4-pentynyl group,1-methyl-2-butynyl group, 2-methyl-3-pentynyl group, 1-hexynyl group and1,1-dimethyl-2-butynyl group.

Examples of the substituent-containing alkynyl group include a2-chloroethynyl group, 2-fluoroethynyl group, 3-fluoro-1-propynyl group,3,3,3-trifluoro-1-propynyl group, 3-fluoro-2-propynyl group and3-iodo-2-propynyl group.

The unsubstituted or substituent-containing aryl group for Z is amonocyclic or polycyclic aryl group. In the polycyclic aryl group,provided at least one ring is an aromatic ring, the remaining ring(s)may each be a saturated alicyclic ring, an unsaturated alicyclic ring oran aromatic ring.

Examples of the unsubstituted aryl group include a phenyl group,1-naphthyl group, 2-naphthyl group, azulenyl group, indenyl group,indanyl group and tetralinyl group.

Examples of the substituent-containing aryl group include a6-methylphenyl group, 4-methylphenyl group, 4-fluorophenyl group,4-chlorophenyl group, 2,4-dichlorophenyl group, 3,4-dichlorophenylgroup, 3,5-dichlorophenyl group, 2,6-difluorophenyl group,4-trifluoromethylphenyl group, 4-methoxyphenyl group,3,4-dimethoxyphenyl group, 3,4-methylenedioxyphenyl group,3-phenoxyphenyl group, 4-trifluoromethoxyphenyl group and4-methoxy-1-naphthyl group.

Examples of the unsubstituted heterocyclic group for Z includeunsaturated heterocyclic 5-membererd ring groups such as a furan-2-ylgroup, furan-3-yl group, thiophen-2-yl group, thiophen-3-yl group,pyrrol-2-yl group, pyrrol-3-yl group, oxazol-2-yl group, oxazol-4-ylgroup, oxazol-5-yl group, thiazol-2-yl group, thiazol-4-yl group,thiazol-5-yl group, isooxazol-3-yl group, isooxazol-4-yl group,isooxazol-5-yl group, isothiazol-3-yl group, isothiazol-4-yl group,isothiazol-5-yl group, imidazol-2-yl group, imidazol-4-yl group,imidazol-5-yl group, pyrazol-3-yl group, pyrazol-4-yl group,pyrazol-5-yl group, 1,3,4-oxadiazol-2-yl group, 1,3,4-thiadiazol-2-ylgroup, 1,2,3-triazol-4-yl group, 1,2,4-triazol-3-yl group and1,2,4-triazol-5-yl group; unsaturated heterocyclic 6-membererd ringgroups such as a pyridin-2-yl group, pyridin-3-yl group, pyridin-4-ylgroup, 5-chloro-3-pyridyl group, 3-trifluoromethyl-2-pyridyl group,pyridazin-3-yl group, pyridazin-4-yl group, pyrazin-2-yl group,pyrimidin-5-yl group, 1,3,5-triazin-2-yl group and 1,2,4-triazin-3-ylgroup; and saturated or partially unsaturated heterocyclic groups suchas a tetrahydrofuran-2-yl group, tetrahydropyran-4-yl group,piperidin-3-yl group, pyrrolidin-2-yl group, morpholino group,piperidino group, piperazino group, N-methylpiperazino group, aziridinogroup, azetidino group, pyrrolidino group and oxazolin-2-yl group.

Examples of the substituent-containing heterocyclic group include a3-trifluoromethylpyridin-2-yl group, 4-trifluoromethoxy-2-pyridyl group,3-methyl-1-pyrazolyl group, 4-trifluoromethyl-1-imidazolyl group and3,4-difluoropyrrolidino group.

The R³ in the OR³, S(O)_(p)R³, COR³ and CO₂R³ groups for Z represents anunsubstituted or substituent-containing amino group, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, or unsubstituted orsubstituent-containing heterocyclic group. Further, p represents thenumber of oxygen atoms within the parentheses, and is an integer of 0 to2.

Examples of the unsubstituted or substituent-containing amino group,unsubstituted or substituent-containing alkyl group, unsubstituted orsubstituent-containing alkenyl group, unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, and unsubstituted orsubstituent-containing heterocyclic group for R³ include the same groupsas those described above for R^(1C) and Z.

Specific examples of OR³ include a methoxy group, ethoxy group,n-propoxy group, i-propoxy group, n-butoxy group, s-butoxy group,i-butoxy group, t-butoxy group, methoxymethoxy group, ethoxymethoxygroup, methoxyethoxy group, ethoxyethoxy group, vinyloxy group,1-propenyloxy group, 2-propenyloxy group, ethynyloxy group,1-propynyloxy group, 2-propynyloxy group, aminooxy group, methylaminooxygroup, diethylaminooxy group, methoxycarbonylaminooxy group, phenoxygroup, trichloromethoxy group, trifluoromethoxy group, difluoromethoxygroup, 2,2,2-trifluoroethoxy group, pentafluoroethoxy group and2-fluoroethoxy group.

Specific examples of S(O)_(p)R³ include a dimethylaminothio group,chloromethylthio group, 3-butenylthio group, ethynylthio group,3-methylphenylthio group, methylsulfinyl group, ethylsulfinyl group,1-butenylsulfinyl group, 1-hexynylsulfinyl group,2,3-dimethylphenylsulfinyl group, methylsulfonyl group,dimethylaminosulfonyl group, N-ethyl-N-methylaminosulfonyl group,n-hexylsulfonyl group, 2-methyl-2-butenylsulfonyl group,2-propynylsulfonyl group, 2-naphthylsulfonyl group, phenylsulfonylgroup, 2-nitrophenylsulfonyl group and p-tolylsulfonyl group.

Specific examples of COR³ include an acetyl group, benzoyl group,propanoyl group, 1-propylcarbonyl group, t-butylcarbonyl group,cyclopropylcarbonyl group, cyclobutylcarbonyl group, cyclopentylcarbonylgroup, vinylcarbonyl group, 1-propenylcarbonyl group, 2-propenylcarbonylgroup, i-propenylcarbonyl group, 1-propynylcarbonyl group,2-propynylcarbonyl group, 3-butenylcarbonyl group, methylaminocarbonylgroup, dimethylaminocarbonyl group, N-methyl-N-ethylaminocarbonyl group,aziridinocarbonyl group, azetidinocarbonyl group, pyrrolidinocarbonylgroup, piperidiniocarbonyl group, morpholinocarbonyl group,piperazinocarbonyl group and N-methylpiperazinocarbonyl group.

Specific examples of CO₂R³ include a methoxycarbonyl group,trifluoromethoxycarbonyl group, 1-pentenyloxycarbonyl group,2-propynyloxycarbonyl group and phenoxycarbonyl group.

Among the above groups, Z in formula (7) is preferably a halogen atom,an unsubstituted or substituent-containing amino group, an unsubstitutedalkyl group, OR³ or SR³, and is more preferably an unsubstituted orsubstituent-containing amino group, an unsubstituted alkyl group, OR³ orSR³. The unsubstituted or substituent-containing amino group for Z ispreferably an unsubstituted amino group or a dialkylamino group, theunsubstituted alkyl group preferably contains 1 to 4 carbon atoms, OR³is preferably an alkoxy group containing 1 to 4 carbon atoms, and SR³ ispreferably an alkylthio group containing 1 to 4 carbon atoms.

The value of m in formula (7) indicates the number of Z substituents,and is an integer of 0 to 3. When m is 2 or more, the plurality of Zsubstituents may be the same as, or different from, each other. It isparticularly preferable that m be 0.

The halogenated picoline derivative represented by formula (7) may beobtained, for example, by reacting the 2-substitutedamino-6-methylpyridine derivative having a corresponding structure witha halogenating agent.

In the step C1, the substance reacted with the halogenated picolinederivative represented by formula (7) is a tetrazolylhydroxyiminoderivative represented by formula (8).

In formula (8), Y represents an unsubstituted or substituent-containingalkyl group. Examples of the unsubstituted or substituent-containingalkyl group for Y include the same groups as those described above forR^(1C). The unsubstituted or substituent-containing alkyl group for Y ispreferably an unsubstituted alkyl group, more preferably anunsubstituted alkyl group containing 1 to 6 carbon atoms, and mostpreferably a methyl group.

In formula (8), A represents a halogen atom, unsubstituted orsubstituent-containing alkyl group, unsubstituted orsubstituent-containing alkoxy group, cyano group, unsubstituted orsubstituent-containing alkylsulfonyl group, nitro group, orunsubstituted or substituent-containing aryl group.

Examples of the halogen atom, unsubstituted or substituent-containingalkyl group, unsubstituted or substituent-containing alkoxy group andunsubstituted or substituent-containing aryl group for A include thesame atoms and groups as those described above for R^(1C) and Z. Theunsubstituted or substituent-containing alkyl group for A is preferablyan unsubstituted alkyl group or haloalkyl group, and is more preferablyan unsubstituted alkyl group containing 1 to 6 carbon atoms or ahaloalkyl group containing 1 to 6 carbon atoms. The unsubstituted orsubstituent-containing alkoxy group for A is preferably an unsubstitutedalkoxy group or haloalkoxy group, and is more preferably anunsubstituted alkoxy group containing 1 to 6 carbon atoms or ahaloalkoxy group containing 1 to 6 carbon atoms.

Examples of the unsubstituted alkylsulfonyl group for A include amethylsulfonyl group, ethylsulfonyl group, n-propylsulfonyl group,i-propylsulfonyl group and t-butylsulfonyl group. Examples of thesubstituent-containing alkylsulfonyl group include a2-pyridylmethylsulfonyl group, 3-pyridylmethylsulfonyl group,chloromethylsulfonyl group, cyanomethylsulfonyl group,1-cyanoethylsulfonyl group, 2-cyanoethylsulfonyl group,nitromethylsulfonyl group, chloromethylsulfonyl group,fluoromethylsulfonyl group, difluoromethylsulfonyl group,trifluoromethylsulfonyl group, 2-fluoroethylsulfonyl group,2,2,2-trifluoroethylsulfonyl group, methoxymethylsulfonyl group,ethoxymethylsulfonyl group, 1-methoxyethylsulfonyl group,2-methoxyethylsulfonyl group and 2-chloroethoxymethylsulfonyl group. Theunsubstituted or substituent-containing alkylsulfonyl group for A ispreferably an unsubstituted alkylsulfonyl group, and more preferably anunsubstituted alkylsulfonyl group containing 1 to 6 carbon atoms.

In formula (8), n_(c) represents the number of A substituents, and is aninteger of 0 to 5. When n, is 2 or more, the plurality of the Asubstituents may be the same as, or different from, each other. It isparticularly preferable that n_(c) be 0.

The reaction between the halogenated picoline derivative represented byformula (7) and the tetrazolylhydroxyimino derivative represented byformula (8) in the step C1 is a conventional reaction that involves acoupling between a halogeno group and a hydroxyl group. The reaction maybe performed, for example, in accordance with the method disclosed inJapanese Unexamined Patent Application, First Publication No.2003-137875 or International Patent Publication No. WO 03/016303pamphlet. The reaction is generally performed in the presence of a base.

Examples of the base used in the reaction include alkali metalhydroxides such as sodium hydroxide and potassium hydroxide; alkalineearth metal hydroxides such as magnesium hydroxide and calciumhydroxide; carbonates such as sodium carbonate, potassium carbonate,magnesium carbonate and calcium carbonate; hydrides such as sodiumhydride and calcium hydride; metal alkoxides such as sodium methoxide,sodium ethoxide and magnesium methoxide; and organic bases such astriethylamine, diisopropylethylamine, pyridine,N,N-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,4-(dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene and1,5-diazabicyclo[4.3.0]non-5-ene. Any one of these bases may be usedalone, or a combination of two or more bases may be used.

The amount used of the base in the step C1 is typically within a rangefrom 0.01 to 100 mols, and preferably from 0.1 to 5 mols, per 1 mol ofthe tetrazolylhydroxyimino derivative represented by formula (8).

The reaction in the step C1 may be conducted in the presence of asolvent or without using a solvent.

There are no particular limitations on the solvent used, provided it isinactive in the reaction. Examples of the solvent includehydrocarbon-based solvents such as pentane, hexane, heptane, benzene,toluene and xylene; halogen-based solvents such as dichloromethane,chloroform and carbon tetrachloride; nitrile-based solvents such asacetonitrile and propionitrile; ether-based solvents such as diethylether, dioxane and tetrahydrofuran; amide-based solvents such asN,N-dimethylformamide, N,N-dimethylacetamide and N-methylpyrrolidone;sulfoxide-based solvents such as dimethylsulfoxide; and mixed solventsof the above solvents.

There are no particular limitations on the procedure and the likeadopted for the reaction between the halogenated picoline derivativerepresented by formula (7) and the tetrazolylhydroxyimino derivativerepresented by formula (8). For example, the reaction may be performedby adding a base and the tetrazolylhydroxyimino derivative representedby formula (8) to an organic solvent solution containing the halogenatedpicoline derivative represented by formula (7).

The temperature during the period from the start of the reaction to thecompletion of the reaction in the step C1 may be either kept at aconstant temperature or varied, but is typically within a range from−70° C. to +200° C., and preferably from −20° C. to +100° C. Thereaction time varies depending on the reaction scale and the like, butis typically within a range from 30 minutes to 24 hours.

By conducting the step C1, a tetrazolyloxime derivative represented byformula (9) can be obtained in an industrially advantageous manner. Thetetrazolyloxime derivative represented by formula (9) is a novelsubstance, and is very useful as a production intermediate for thetetrazolyloxime derivative represented by formula (10) described below.

In formula (9), R^(1C), R^(2C), Z, m, A, n_(c) and Y are the same asdefined above in formula (7) or formula (8).

[Step C2]

Next, in the step C2, the tetrazolyloxime derivative represented byformula (10) may be obtained by treating the reaction product obtainedin the step C1 with a base.

The reaction product obtained in the step C1, namely the tetrazolyloximederivative represented by formula (9), may be reacted with a basewithout performing any purification operation of the reaction solutionobtained in the step C1, or alternatively, the reaction solutionobtained in the step C1 may be subjected to a purification operation toisolate the reaction product, namely the tetrazolyloxime derivativerepresented by formula (9), which may then be treated with a base.Examples of the purification operation include distillation,recrystallization and column chromatography.

There are no particular limitations on the base used in the step C2,provided it is capable of eliminating the R^(2C) group from thetetrazolyloxime derivative represented by formula (9). Examples of thebase include alkali metal hydroxides such as sodium hydroxide andpotassium hydroxide; alkaline earth metal hydroxides such as magnesiumhydroxide and calcium hydroxide; carbonates such as sodium carbonate,potassium carbonate, magnesium carbonate and calcium carbonate; hydridessuch as sodium hydride and calcium hydride; metal alkoxides such assodium methoxide, sodium ethoxide and magnesium methoxide; and organicbases such as triethylamine, diisopropylethylamine, pyridine,N,N-dimethylaminopyridine, 1,4-diazabicyclo[2.2.2]octane,4-(dimethylamino)pyridine, 1,8-diazabicyclo[5.4.0]undec-7-ene and1,5-diazabicyclo[4.3.0]non-5-ene. Any one of the bases may be usedalone, or a combination of two or more bases may be used.

The amount used of the base in the step C2 is typically within a rangefrom 0.01 to 100 mols, and preferably from 0.1 to 5 mols, per 1 mol ofthe tetrazolyloxime derivative represented by formula (9). When thereaction solution obtained in the step C1 is used in the step C2 withoutremoving the base therefrom, the amount of base added in the step C2 maybe adjusted taking into account the amount used in the step C1.

The reaction in the step C2 may be conducted in the presence of asolvent or in the absence of a solvent. There are no particularlimitations on the solvent used, provided it is inactive in thereaction. Specific examples of the solvent include the same solvents asthose described above for the step C1. If the solvent used in the stepC2 is the same as the solvent used in the step C1, there is no need toperform a solvent substitution when transitioning from the step C1 tothe step C2, which is advantageous in terms of production costs.

There are no particular limitations on the procedure and the likeadopted for treating the reaction product obtained in the step C1 with abase. For example, the reaction may be performed by adding a base to anorganic solvent solution containing the reaction product obtained in thestep C1, namely the tetrazolyloxime derivative represented by formula(9).

The temperature during the period from the start of the reaction to thecompletion of the reaction in the step C2 may be either kept at aconstant temperature or varied, but is typically within a range from 0°C. to the boiling point of the solvent, and is preferably within a rangefrom 10 to 60° C. The reaction time varies depending on theconcentration of the base and the reaction scale and the like, but istypically within a range from 5 minutes to 24 hours.

By performing the step C2, the tetrazolyloxime derivative represented byformula (10) can be obtained in an industrially advantageous manner.

In formula (10), R^(1C), Z, m, A, n_(c) and Y are the same as definedabove in formula (7) or formula (8).

Following completion of the reaction of the step C2, typicalpost-processing operations may be performed. The targetedtetrazolyloxime derivative represented by formula (10) can then beisolated. Further, in those cases where further purification of theproduct is required, conventional purification methods such asdistillation, extraction, recrystallization or column chromatography maybe employed.

The structure of the target product may be identified and confirmed bymeasuring the ¹H-NMR spectrum, IR spectrum and mass spectrum, and byelemental analysis and the like.

The tetrazolyloxime derivative represented by formula (10) obtainedusing the production method according to the present invention may beconverted to a salt. The salt may be produced in accordance with normalmethods, by treating the tetrazolyloxime derivative represented byformula (10) with an acid.

The tetrazolyloxime derivative represented by formula (10) or a saltthereof, obtained using the production method according to the presentinvention, is ideal as an active ingredient of fungicides or the like.The fungicides may be used, for example, as agrochemical formulationsthat assist the growth of agricultural and horticultural crops, asantifouling agents that prevent the adhesion of crustaceans andshellfish, and as antibacterial and moldproofing reagents for walls andbathrooms, or shoes and clothing.

EXAMPLES

The present invention is described below in further detail based on aseries of examples, but the present invention should not be interpretedas being limited to only these examples.

Example A1

10.52 g (2.5 mmol) of a compound (a) was dissolved in 1.25 ml of toluene(0.5 L/mol). The solution of the compound (a) was then added dropwise,at room temperature, to a liquid prepared by adding 0.13 g of sodiumhydride (55%) (1.2 eq.) to a mixture solvent composed of toluene andN,N-dimethylformamide at a ratio of 4/1 (2 L/mol), and the resultingmixture was then aged at room temperature for 30 minutes.

Subsequently, 0.42 g (1.2 eq.) of benzoyl chloride was added dropwise tothe reaction mixture under cooling, and the resulting mixture was agedat the temperature for 20 minutes.

The reaction mixture was extracted twice with ethyl acetate (2 L/mol),and the extract was then washed with a saturated saline solution (2L/mol), dried over anhydrous magnesium sulfate, filtered, andconcentrated. The thus obtained crystals were then washed with cooledn-hexane (2 L/mol). A compound represented by formula (b) (hereafterreferred to as “compound (b)”) was obtained in an amount of 0.66 g. Theyield was 84.6%.

Example A2

(Bromination)

0.31 g (1 mmol) of the compound (b) was dissolved in 4 ml ofchlorobenzene (4 L/mol), and then 0.29 g (1 eq.) of2,5-di-t-butylhydroquinone and 0.03 g (0.2 eq.) of2,2′-azobisisobutyronitrile were added sequentially to the resultantsolution, followed by stirring at 90° C. for one hour. The resultantliquid was then cooled to room temperature. The resultant liquid wasthen washed with a 1 N aqueous solution of sodium hydroxide and driedover anhydrous magnesium sulfate, followed by removing the solventtherefrom by distillation under reduced pressure. The residue waspurified by silica gel column chromatography (developing solvent:hexane/ethyl acetate=3/1), yielding 0.15 g (yield: 38%) of a compoundrepresented by formula (c).

Using the same procedure as that described for the above productionmethod, a compound represented by formula (1-a) shown in Table 1, acompound represented by formula (1-b) shown in Table 2, and a compoundrepresented by formula (1) shown in Table 3 were obtained. The physicalproperties and the like of the compounds are shown in Table 1 and Table2. In the tables, MeOCO represents a methoxycarbonyl group, EtOCOrepresents an ethoxycarbonyl group, Ac represents an acetyl group, andBz represents a benzoyl group.

TABLE 1 Com- pound Physical number R¹ properties NMR a-1 MeOCO m.p. 57.5to 57.6° C. a-2 EtOCO ¹H-NMR (CDCl₃) δ ppm: 1.2 (t, 3H), 1.4 (s, 9H),2.5 (s, 3H), 4.2 (q, 2H), 7.0 (d, 1H), 7.1 (d, 1H), 7.6 (t, 1H) a-3 Acm.p. 77.4 to 77.5° C. a-4 Bz m.p. 93.7 to 93.8° C. a-5 p-NO₂-Bz m.p.114.8 to 114.9° C.

TABLE 2 Com- pound Physical number X n R¹ properties NMR a-6 Br 1 MeOCOm.p. 82.8 to 82.9° C. a-7 Br 1 EtOCO m.p. 63.9 to 64.0° C. a-8 Br 1 Acm.p. 98.6 to 100.4° C. a-9 Br 1 Bz ¹H-NMR (CDCl₃) δ ppm: 1.3 (s, 9H),4.4 (s, 2H), 7.29 (d, 1H), 7.34 (d, 1H), 7.4 (d, 2H), 7.5 (d, 1H), 7.8(m, 3H) a-10 Cl 1 Bz ¹H-NMR (CDCl₃) δ ppm: 1.3 (s, 9H), 4.6 (s, 2H), 7.3(d, 1H), 7.45 (m, 3H), 7.5 (d, 1H), 7.8 (m, 3H) a-11 Cl 1 p-NO₂-Bz m.p.89.5 to 89.6° C.

TABLE 3 Compound number R⁰ R¹ (Z)m (X)n a-12 tBuO MeOCO H F a-13 tBuOEtOCO H Cl a-14 tBuO Ac H Br₃ a-15 tBuO Bz H I a-16 tBuO p-NO₂-Bz H Br₂a-17 MeOCH₂O MeOCO H H a-18 EtOC₂H₄CH(Me)O Bz H H a-19 iPrOC₃H₆O Ac H Ha-20 (MeO)₂CHCH₂C(Me)₂O EtOCO H H a-21 MeOC₂H₄CH(EtO)O Ac H H a-22MeOCH₂ Bz H Br₂ a-23 (MeO)₂CH₂ p-NO₂-Bz H Br a-24 MeC(EtO)₂ Ac H H a-25(MeO)₂C₂H₄ MeOCO H H a-26 EtOCH₂ EtOCO H H a-27 1,3-dioxane-2-yl-methylMeOCO H H a-28 1,3-dioxane-2-yl-ethyl EtOCO H F a-291,3-dioxane-2-yl-propyl Ac H Cl a-30 1,3-dioxane-2-yl-buthyl Bz H Bra-31 1,3-dioxane-2-yl-penthyl p-NO₂-Bz H I a-32 MeC═NOMe MeOCO H H a-33MeC═NOnPr EtOCO H H a-34 EtC═NOEt Ac H H a-35 nPrC═NOMe Bz H H a-36iPrC═NOMe p-NO₂-Bz H H

Example B1 Production of t-butylbenzoyl-(6-methyl-pyridin-2-yl)-carbamate

A reactor that had been flushed with nitrogen was charged with 40 ml ofN,N-dimethylformamide, and then 5.23 g of sodium hydride (purity: 55%)and 160 ml of toluene were added to the reactor. A solution containing20.8 g of t-butyl (6-methyl-pyridin-2-yl)-carbamate in 50 ml of toluenewas added dropwise to the suspension in the reactor over a period of 20minutes and within a temperature range from 20° C. to 25° C. Followingcompletion of the dropwise addition, the mixture was stirred for 30minutes at a temperature within a range from 20° C. to 25° C.Subsequently, the reaction mixture was cooled to 5° C. or lower, and13.9 ml of benzoyl chloride was added dropwise over a period of 15minutes and within a temperature range from 0° C. to 5° C. Followingcompletion of the dropwise addition, the mixture was stirred for 10minutes at a temperature within a range from 0° C. to 5° C.Subsequently, the reaction mixture was poured into 200 ml of ice water,and the organic layer and the aqueous layer were separated. The aqueouslayer was extracted with 20 ml of toluene, and the extract was mixedwith the previously separated organic layer. The resultant was washedtwice with 50 ml of water, and then washed once with 50 ml of asaturated saline solution. The solvent was removed by distillation underreduced pressure. Hexane was added to the residue, and the mixture wasconcentrated under reduced pressure. 50 ml of hexane was further addedto the residue, and the mixture was heated at 60° C. The mixture wasthen cooled gradually to 10° C., and stirred for 30 minutes at atemperature of 10° C. or lower. The mixture was then filtered. The solidmatter was washed twice with 20 ml of hexane, and then dried by heating,to obtain 29.1 g (93%) of a compound represented by formula (d).

Example B2 Production of t-butylbenzoyl-(6-bromomethyl-pyridin-2-yl)-carbamate

First, 29.1 g of t-butyl benzoyl-(6-methyl-pyridin-2-yl)-carbamate wasdissolved in 372 ml of chlorobenzene. To the resultant solution wasadded 7.8 g of sodium hydrogen carbonate. The resultant mixture was thenheated to 90° C., and then 3.1 g of azobisisobutyronitrile was addedthereto, followed by adding 26.6 g of 1,3-dibromo-5,5-dimethylhydantoinin 10 portions over a period of 80 minutes. Following completion of theaddition, the mixture was stirred at 90° C. for 30 minutes. The reactionmixture was then cooled to room temperature, washed with 140 ml of 1 Nsodium hydroxide, and then washed with a mixed solution composed of 70ml of water and 23 ml of a saturated saline solution.

The thus obtained organic layer was cooled at 5° C. or lower, and then14.9 g of a 50% solution of sodium hydroxide, 12.0 ml of diethylphosphite and 1.5 g of tetrabutylammonium chloride were each added inportions, while the progression of the reaction was confirmed bythin-layer chromatography. Following completion of the additions, themixture was stirred for 15 minutes at a temperature within a range from0° C. to 5° C.

The disappearance of the spots corresponding with the dibromo compoundsand the tribromo compound and the production of the compound representedby formula (e) (the monobromo compound) were confirmed by performingthin-layer chromatography. The reaction solution was directly used inexample B3 without subjecting to any post-processing.

Example B3 Production of t-butylbenzoyl-{6-([Z]-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamate

To the reaction solution obtained in the example B2 was added 37.2 g ofa 20% solution of sodium hydroxide, and the resulting mixture wasstirred for 30 minutes at a temperature within a range from 20° C. to25° C. Subsequently, 18.9 g of(1-methyl-1H-5-tetrazolyl)-phenyl-methanone-oxime was added, and thereaction mixture was stirred for 3.5 hours at a temperature within arange from 20° C. to 25° C.

The disappearance of the target substance and the production of acompound represented by formula (f) were confirmed by performingthin-layer chromatography. The reaction solution was directly used inexample B4 without subjecting to any post-processing.

Example B4 Production of t-butyl{6-([Z]-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamate

To the reaction solution obtained in the example B3 was added 37.2 g ofa 20% solution of sodium hydroxide, and the resulting mixture wasstirred at 40° C. for 15 hours. The disappearance of the raw materialsand the production of the target product were confirmed by performingthin-layer chromatography. Subsequently, the reaction mixture wasseparated into an organic layer and an aqueous layer. The organic layerwas washed with 93 ml of 1 N sodium hydroxide. The aqueous layer wasextracted with 23 ml of chlorobenzene, and the extract was mixed withthe previously separated organic layer, followed by washing the mixturewith 47 ml of a saturated saline solution. The solvent was removed bydistillation under reduced pressure, and then methanol was added to theresidue, followed by concentrating the mixture under reduced pressure.The process of adding methanol and performing concentration underreduced pressure was further repeated twice. Subsequently, 47 ml ofmethanol was added to the resultant, and the mixture was heated underreflux to obtain a homogenous solution. The solution was then cooledgradually to 10° C., and stirred for 30 minutes at a temperature of 10°C. or lower. The resulting liquid was then filtered. The solid matterwas washed twice with 19 ml of methanol, and then dried under heat,yielding 26.6 g of a compound represented by formula (g). The meltingpoint of the solid material was 141.5 to 141.6° C. The through-yieldfrom the t-butyl benzoyl-(6-methyl-pyridin-2-yl)-carbamate (example B2)was 70%.

Example B5 Production of t-butylacetyl-(6-methyl-pyridin-2-yl)-carbamate

With the exception of using acetyl chloride instead of benzoyl chloride,the same procedure as the production example B1 was used to produce acompound represented by formula (h). The melting point of the compoundwas 77.4 to 77.5° C.

Example B6 Production of t-butylacetyl-(6-bromomethyl-pyridin-2-yl)-carbamate

First, 1.05 g (4.2 mmol) of t-butylacetyl-(6-methyl-pyridin-2-yl)-carbamate was dissolved in 17 ml ofchlorobenzene (4 L/mol). 1.2 g (1 eq.) of1,3-dibromo-5,5-dimethylhydantoin and 0.14 g (20 mol %) of2,2′-azobisisobutyronitrile were added to the resulting solution, andthe resulting mixture was stirred at 90° C. for one hour. Subsequently,the reaction mixture was cooled, the precipitate was removed byfiltration, and the filtrate was concentrated to approximately halfvolume.

To the thus obtained residue were added, under cooling, 0.58 g ofdiethyl phosphite and 0.54 g of diisopropylethylamine, and the resultingmixture was stirred at room temperature for 19 hours. The disappearanceof the raw materials was confirmed by performing thin-layerchromatography (ethyl acetate:hexane=1:4 (volumetric ratio)), and thenthe resultant was extracted with chloroform three times. The extract wasdried over anhydrous magnesium sulfate and filtered, and the solvent wasthen removed by distillation under reduced pressure.

Example B7 Production of t-butyl{6-([Z]-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamate

First, 0.85 g of (1-methyl-1H-5-tetrazolyl)-phenyl-methanone-oxime wasdissolved in 6 ml of chlorobenzene (1.5 L/mol). To the resultingsolution were added dropwise, at 0° C., 1.75 ml (2 eq.) of a 20% aqueoussolution of sodium hydroxide, 0.27 g (20 mol %) of tetrabutylammoniumbromide, and a solution prepared by dissolving the residue obtained inthe example B6 in 3 ml of chlorobenzene (0.8 L/mol). The resultingmixture was stirred overnight at room temperature. Followingconfirmation by performing thin-layer chromatography (ethylacetate:hexane=1:4) that the raw materials had disappeared, the reactionmixture was extracted with chloroform three times. The organic layer wasdried over anhydrous magnesium sulfate and filtered, and the solvent wasthen removed by distillation under reduced pressure. The residue waspurified using an automated fraction collector (manufactured by YamazenCorporation), yielding t-butylacetyl-{6-([Z]-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamatein a yield of 67.4%.

Next, 1.28 g (2.835 mmol) of the thus obtained t-butylacetyl-{6-([Z]-(1-methyl-1H-5-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamatewas dissolved in 23 ml of methanol (8 L/mol). To the resulting solutionwas added 3.51 ml (3 eq.) of a 10% aqueous solution of sodium hydroxide,and the resulting mixture was stirred at room temperature for 15 hours.Subsequently, the reaction liquid was concentrated. The resultingconcentrate was washed with water, washed with hexane, and then washedwith a small amount of methanol. The product was then air-dried,yielding 0.98 g of the target compound (yield: 84.5%). The through-yieldfrom the t-butyl acetyl-(6-methyl-pyridin-2-yl)-carbamate (example B6)was 73.8%.

Example B8 Production of t-butylt-butoxycarbonyl-(6-methyl-pyridin-2-yl)-carbamate

First, 38 g of 6-methyl-pyridin-2-ylamine, 169 g ofbis(t-butoxycarbonyl) oxide, 18 ml (2.48 g) of triethylamine and 18 ml(1.84 g) of pyridine were dissolved in 340 ml of dimethylformamide. Theresulting solution was then heated gradually. The liquid temperature waseventually raised to 90° C. while monitoring the state of generatedcarbon dioxide. The reaction mixture was then held at the temperaturefor 5 hours. Following confirmation by performing thin-layerchromatography that the raw materials had disappeared, the reactionmixture was poured into a mixed solution containing 500 ml of each of asaturated aqueous solution of ammonium chloride, a saturated aqueoussolution of sodium hydrogen carbonate and a saturated aqueous solutionof sodium chloride, and the resulting mixture was then extracted withethyl acetate. The extract was then dried over anhydrous magnesiumsulfate, filtered and concentrated. Subsequently, a column purificationwas performed, yielding 81 g (74.7%) of the target product.

Example B9 Production of2-bis(t-butoxycarbonyl)amino-6-bromomethyl-pyridine

To 102.8 g (334 mmol) of t-butylt-butoxycarbonyl-(6-methyl-pyridin-2-yl)-carbamate were added 10.95 g(20 mol %) of 2,2′-azobisisobutyronitrile and 1,330 ml of chlorobenzene.To the resulting mixture was added 95.31 g of1,3-dibromo-5,5-dimethylhydantoin, and the temperature of the mixturewas then raised to 90° C. at a rate of 2° C./minute and held at thetemperature for one hour. Subsequently, the reaction mixture was cooledto 20° C., the precipitate was filtered off, and the volume ofchlorobenzene was reduced by half by distillation. The thus obtainedresidue was cooled to 10° C. or lower, and then 46.03 g (43 ml) ofdiisopropylethylamine and 43.08 g (58 ml) of diethyl phosphite wereadded thereto, followed by aging the mixture at room temperature for16.5 hours. Following confirmation by performing thin-layerchromatography that the raw materials had disappeared, the reactionmixture was washed with 300 ml of 3 N hydrochloric acid, and thenfurther washed with 500 ml of a saturated saline solution. The resultingsolution was then dried over anhydrous magnesium sulfate and filtered,yielding a solution of2-bis(t-butoxycarbonyl)amino-6-bromomethyl-pyridine.

Example B10 Production of t-butyl{6-([Z]-(1-methyl-1H—S-tetrazolyl)phenylmethylene-aminooxymethyl)-2-pyridyl}carbamate

To the solution of 2-bis(t-butoxycarbonyl)amino-6-bromomethyl-pyridineobtained in the example B9 were added 67.7 g of(1-methyl-1H-5-tetrazolyl)-phenyl-methanone-oxime, 667 ml of a 1 Naqueous solution of sodium hydroxide and 5.4 g (5 mol %) oftetrabutylammonium bromide, and the resulting mixture was aged at roomtemperature for two hours. Following confirmation by performingthin-layer chromatography that the raw materials had disappeared, 500 mlof water and 500 ml of chloroform were added, and an extraction wasperformed. The aqueous layer was extracted with 500 ml of chloroform,and then washed with 500 ml of water. The extract was dried overanhydrous magnesium sulfate, filtered and then concentrated. The thusobtained residue was dissolved in 2.5 L of methanol, and 1 L of a 1 Naqueous solution of sodium hydroxide was then added to the solution atroom temperature. The reaction was allowed to proceed at roomtemperature for approximately 20 hours.

The precipitated crystals were collected by filtration. The thusobtained crystals were washed three times with 500 ml of water, and thendried in a desiccator, yielding 98.16 g of the Z-isomer of the targetproduct (purity: 98.5%, yield: 72.6%). On the other hand, 5 L of waterwas added to the above filtrate, and the mixture was extracted threetimes with 1,000 ml of ethyl acetate. The ethyl acetate layer was washedwith 1 L of water, dried over anhydrous magnesium sulfate, filtered, andthen concentrated. The thus obtained residue was purified using afraction collector manufactured by Biotage AB, yielding 6.1 g of thetarget product (E:Z isomeric mixture). The total yield was 77.1%.

Example C1

To 54.7 g of a solution prepared by dissolving 5.87 g (15 mmol) of acompound represented by formula (n) in 44 mL of chlorobenzene were added48.0 g (60 mmol) of an aqueous solution of NaOH having a concentrationof 5% by weight, 0.24 g (0.75 mmol) of tetrabutylammonium bromide, and3.77 g (purity: 97.0% by weight, 18 mmol) of a compound represented byformula (o).

The resulting mixture was stirred at room temperature for 4 hours, andthe disappearance of the compound represented by formula (n) and theproduction of a compound represented by formula (p) were confirmed byhigh-performance liquid chromatography.

The reaction mixture was heated to 40° C., and 4.29 g (30 mmol) of anaqueous solution of NaOH having a concentration of 28% by weight wasadded. The mixture was then stirred at 40° C. for 2.5 hours.Subsequently, the mixture was left to stand overnight, and was thenagain stirred at 40° C. for 3.5 hours. The reaction mixture wasseparated, and the thus obtained organic phase was washed sequentiallywith an aqueous solution of NaOH having a concentration of 1 mol/L andwater. Following washing, the organic phase was concentrated using anevaporator, and the resulting residue was crystallized from methanol,yielding 6.08 g (14.8 mmol, yield: 99%) of white crystals.

The obtained white crystals exhibited the same physical property valuesas the compound labeled as compound number (3)-8 in Table 3 of WO03/016303. The obtained white crystals were confirmed as being thecompound represented by formula (q).

Example C2

First, 0.47 g (1.28 mmol) of the compound represented by formula (n) wasdissolved in 5 mL of acetonitrile, and then 0.2 g (1.4 mmol) ofpotassium carbonate was added thereto. Subsequently, 0.3 g (1.4 mmol) ofthe compound represented by formula (o) was added, and the mixture wasstirred at room temperature for 30 minutes. The mixture was then left tostand overnight. Next, the reaction mixture was filtered and thenconcentrated under reduced pressure. The thus obtained residue waspurified by column chromatography, yielding 300 mg (0.58 mmol, yield:46%) of white crystals. The NMR measurement results for the thusobtained white crystals were as follows.

¹H-NMR (CDCl₃, δ ppm): 1.25 (s, 9H), 3.87 (s, 3H), 5.30 (s, 2H), 7.21 to7.81 (m, 13H).

The obtained white crystals were confirmed as being the compoundrepresented by formula (p).

Example C3

With the exception of replacing the compound represented by formula (n)with 2-(t-butoxycarbonylmethoxycarbonylamino)-6-bromomethyl-pyridine,the same procedure as the example C2 yielded a compound represented byformula (r). The NMR measurement results for the compound represented byformula (r) were as follows.

¹H-NMR (CDCl₃, δ ppm): 1.41 (s, 9H), 3.77 (s, 3H), 3.79 (s, 3H), 5.38(s, 2H), 7.18 (d, 1H), 7.26 (d, 1H), 7.37 (m, 2H), 7.45 (m, 1H), 7.51(m, 1H), 7.78 (t, 1H).

INDUSTRIAL APPLICABILITY

The compound containing a pyridine ring according to the presentinvention can be synthesized in an industrially advantageous manner, andis useful as an intermediate for producing tetrazolyloxime derivativesthat exhibit fungicidal activity. Further, the production methodaccording to the present invention enables 2-substitutedamino-6-halomethylpyridine derivatives to be obtained with highselectivity and in high yield, and enables the production, in anindustrially advantageous manner, of tetrazolyloxime derivatives thatexhibit excellent antagonistic effects against plant diseases.

1. A compound comprising a pyridine ring, represented by formula (1):

wherein R⁰ represents a C₁₋₆ alkoxy group, a C₁₋₆ alkoxy-C₁₋₆ alkoxygroup, a C₁₋₆ alkoxy-C₁₋₆ alkyl group, a 1,3-dioxane-2-yl-C₁₋₆ alkylgroup, or a CR⁰¹C(═NOR⁰²) group (wherein each of R⁰¹ and R⁰²independently represents a C₁₋₆ alkyl group), R¹ represents a C₁₋₂alkoxycarbonyl group, an acetyl group, or a benzoyl group that may besubstituted with a nitro group, Z represents a halogen atom, a cyanogroup, a nitro group, a hydroxyl group, a thiol group, a formyl group, acarboxyl group, an unsubstituted or substituent-containing amino group,an unsubstituted or substituent-containing alkyl group, an unsubstitutedor substituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, an unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), m representsa number of Z substituents and is an integer of 0 to 3, and when m is 2or more, a plurality of the Z substituents may be identical to, ordifferent from, each other, X represents a halogen atom, and nrepresents a number of X substituents and is an integer of 0 to 3, andwhen n is 2 or more, a plurality of X atoms may be identical to, ordifferent from, each other.
 2. A method for producing a halogenatedpicoline derivative represented by formula (3), the method comprising: astep B1 in which a compound represented by formula (2) and ahalogenating agent are reacted in an organic solvent; and a step B2 inwhich a reaction product obtained in the step B1 is reduced,

wherein R^(1b) represents an unsubstituted or substituent-containingalkoxycarbonyl group, R^(2b) represents an unsubstituted orsubstituent-containing alkoxycarbonyl group, an unsubstituted orsubstituent-containing acyl group, an unsubstituted orsubstituent-containing aryloxycarbonyl group, or an unsubstituted orsubstituent-containing heterocyclic oxycarbonyl group, Z represents ahalogen atom, a cyano group, a nitro group, a hydroxyl group, a thiolgroup, a formyl group, a carboxyl group, an unsubstituted orsubstituent-containing amino group, an unsubstituted orsubstituent-containing alkyl group, an unsubstituted orsubstituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, an unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), and mrepresents a number of Z substituents and is an integer of 0 to 3, andwhen m is 2 or more, a plurality of the Z substituents may be identicalto, or different from, each other,

wherein R^(1b), R^(2b), Z and m are as defined above, and X represents ahalogen atom.
 3. The method for producing a halogenated picolinederivative according to claim 2, wherein the step B1 is performed inpresence of a base.
 4. The method for producing a halogenated picolinederivative according to claim 2 or 3, wherein the organic solvent in thestep B1 is benzene or a halogenated hydrocarbon.
 5. The method forproducing a halogenated picoline derivative according to claim 2 or 3,wherein the step B2 is performed in presence of a phase transfercatalyst.
 6. The method for producing a halogenated picoline derivativeaccording to claim 2 or 3, wherein the halogenating agent is abrominating agent, and X represents a bromine atom.
 7. A method forproducing a brominated picoline derivative represented by formula (6),the method comprising reacting a brominated picoline derivativerepresented by formula (4) and/or formula (5), a phosphite ester, and abase in an organic solvent,

wherein R^(1b) represents an unsubstituted or substituent-containingalkoxycarbonyl group, R^(2b) represents an unsubstituted orsubstituent-containing alkoxycarbonyl group, an unsubstituted orsubstituent-containing acyl group, an unsubstituted orsubstituent-containing aryloxycarbonyl group, or an unsubstituted orsubstituent-containing heterocyclic oxycarbonyl group, Z represents ahalogen atom, a cyano group, a nitro group, a hydroxyl group, a thiolgroup, a formyl group, a carboxyl group, an unsubstituted orsubstituent-containing amino group, an unsubstituted orsubstituent-containing alkyl group, an unsubstituted orsubstituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, an unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), and mrepresents a number of Z substituents and is an integer of 0 to 3, andwhen m is 2 or more, a plurality of the Z substituents may be identicalto, or different from, each other.
 8. A method for producing atetrazolyloxime derivative represented by formula (10), the methodcomprising: a step C1 in which a halogenated picoline derivativerepresented by formula (7) is reacted with a tetrazolylhydroxyiminoderivative represented by formula (8) to obtain a tetrazolyloximederivative represented by formula (9); and a step C2 in which thetetrazolyloxime derivative represented by formula (9) obtained in thestep C1 is treated with a base,

wherein within formula (7), R^(1C) represents an unsubstituted orsubstituent-containing alkyl group, or an unsubstituted orsubstituent-containing alkoxy group, R^(2C) represents an unsubstitutedor substituent-containing alkoxycarbonyl group, or an unsubstituted orsubstituent-containing acyl group, X represents a halogen atom, Zrepresents a halogen atom, a cyano group, a nitro group, a hydroxylgroup, a thiol group, a formyl group, a carboxyl group, an unsubstitutedor substituent-containing amino group, an unsubstituted orsubstituent-containing alkyl group, an unsubstituted orsubstituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, an unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), and mrepresents a number of Z substituents and is an integer of 0 to 3, andwhen m is 2 or more, a plurality of the Z substituents may be identicalto, or different from, each other, and within formula (8), Y representsan unsubstituted or substituent-containing alkyl group, A represents ahalogen atom, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkoxy group, a cyano group, anunsubstituted or substituent-containing alkylsulfonyl group, a nitrogroup, or an unsubstituted or substituent-containing aryl group, andn_(c) represents a number of A substituents and is an integer of 0 to 5,and when n_(c) is 2 or more, a plurality of the A substituents may beidentical to, or different from, each other.
 9. A tetrazolyloximederivative represented by formula (9):

wherein R^(1C) represents an unsubstituted or substituent-containingalkyl group, or an unsubstituted or substituent-containing alkoxy group,R^(2C) represents an unsubstituted or substituent-containingalkoxycarbonyl group, or an unsubstituted or substituent-containing acylgroup, Z represents a halogen atom, a cyano group, a nitro group, ahydroxyl group, a thiol group, a formyl group, a carboxyl group, anunsubstituted or substituent-containing amino group, an unsubstituted orsubstituent-containing alkyl group, an unsubstituted orsubstituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, an unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), m representsa number of Z substituents and is an integer of 0 to 3, and when m is 2or more, a plurality of the Z substituents may be identical to, ordifferent from, each other, Y represents an unsubstituted orsubstituent-containing alkyl group, A represents a halogen atom, anunsubstituted or substituent-containing alkyl group, an unsubstituted orsubstituent-containing alkoxy group, a cyano group, an unsubstituted orsubstituent-containing alkylsulfonyl group, a nitro group, or anunsubstituted or substituent-containing aryl group, and n_(c) representsa number of A substituents and is an integer of 0 to 5, and when n, is 2or more, a plurality of the A substituents may be identical to, ordifferent from, each other.
 10. A method for producing a tetrazolyloximederivative represented by formula (9), the method comprising: a step C1in which a halogenated picoline derivative represented by formula (7) isreacted with a tetrazolylhydroxyimino derivative represented by formula(8),

wherein R^(1C) represents an unsubstituted or substituent-containingalkyl group, or an unsubstituted or substituent-containing alkoxy group,R^(2C) represents an unsubstituted or substituent-containingalkoxycarbonyl group, or an unsubstituted or substituent-containing acylgroup, X represents a halogen atom, Z represents a halogen atom, a cyanogroup, a nitro group, a hydroxyl group, a thiol group, a formyl group, acarboxyl group, an unsubstituted or substituent-containing amino group,an unsubstituted or substituent-containing alkyl group, an unsubstitutedor substituent-containing alkenyl group, an unsubstituted orsubstituent-containing alkynyl group, unsubstituted orsubstituent-containing aryl group, unsubstituted orsubstituent-containing heterocyclic group, OR³, S(O)_(p)R³, COR³ orCO₂R³ (wherein R³ represents an unsubstituted or substituent-containingamino group, an unsubstituted or substituent-containing alkyl group, anunsubstituted or substituent-containing alkenyl group, an unsubstitutedor substituent-containing alkynyl group, an unsubstituted orsubstituent-containing aryl group, or an unsubstituted orsubstituent-containing heterocyclic group, and p represents a number ofoxygen atoms in parentheses, and is an integer of 0 to 2), m representsa number of Z substituents and is an integer of 0 to 3, and when m is 2or more, a plurality of the Z substituents may be identical to, ordifferent from, each other, Y represents an unsubstituted orsubstituent-containing alkyl group, A represents a halogen atom, anunsubstituted or substituent-containing alkyl group, an unsubstituted orsubstituent-containing alkoxy group, a cyano group, an unsubstituted orsubstituent-containing alkylsulfonyl group, a nitro group, or anunsubstituted or substituent-containing aryl group, and n_(c) representsa number of A substituents and is an integer of 0 to 5, and when n_(c)is 2 or more, a plurality of the A substituents may be identical to, ordifferent from, each other.